This website is best viewed in a browser that supports web standards.

Skip to content or, if you would rather, Skip to navigation.

Northwest Missouri State University


Shelley Riley

Shelley Riley

Email

Office

2643 Garrett-Strong

Phone

660.562.1605
660.562.1188 (fax)

Joined Northwest in 2009

Assistant Professor


Education

  • Ph.D Pharmaceutical Chemistry, University of Kansas
  • M.S. Pharmaceutical Chemistry, University of Kansas
  • B.S. Chemistry, Northwest Missouri State University

Courses Taught

  • 24-114/115 General Chemistry I and Lab
  • 24-117 General Chemistry II Lab
  • 24-135 Laboratory Safety
  • 24-499 Special Investigations in Chemistry
  • 24-522/523 Instrumental Analysis and Lab
  • 24-592 Chemistry Seminar

Academic Interests

  • Elemental Analysis
  • Thermal Analysis of Solids
  • Separation Methods and Spectroscopy Applications

Scholarly Activity

  • Dr. Riley's research interests are in Solid State Characterization of Pharmaceuticals and Formulation/Characterization of Nanosuspensions for Oral Drug Delivery.

Selected Publications/Patents

  • Rabel Riley, S.R.; Vickery, R.D.;  Nemeth, G.A.;  Haas, M.J.; Kasprzak, D.J. Maurin, M.B.  Thermal Decomposition of Matrix Metalloproteinase Inhibitors;  Evidence of a Solid State Dimerization.  J. Pharm. Biomed. Anal. 2011, 54, 324-330.
  • Murphy, D. and Rabel, S. Thermal Analysis and Calorimetric Methods for Characterization of New Crystalline Forms.  In:  Preformulation in Solid Dosage Form Development;  Adeyeye, C., Brittain, H., Eds.; Informa Healthcare USA, Inc.; Mew York, NY, 2008, p 279 - 322.
  • Method for screening of solid dispersion formulations of low-solubility compounds-Miniaturization and automation of solvent casting and dissolution testing.   Anant Shanbhag, Shelley Rabel, Ewa Nauka, Gemma Casadevall, Padmaja Shivanand, Gary Eichenbaum, Paul Mansky.   International Journal of Pharmaceutics, Volume 351, Issues 1-2, 209-218. March 3, 2008.
  • P. J. Gilligan, S. R. Rabel Riley, P.A. Meenan.  Salt and Crystalline Form Thereof of a Corticotrophin Releasing Factor Receptor Antagonist.  U.S. Patent 7153961 B2, Dec. 26, 2006
  • L. Radesca, James R. Moore, S. R. Rabel, and M. B. Maurin,  Crystalline Efavirenz.  U.S. Patent 6673372, Jan. 6, 2004.
  • Polymorphism of Roxifiban.  Michael B. Maurin, Rodney D. Vickery, Shelley R. Rabel, Susan M. Rowe, J. Gerry Everlof, Gregory A. Nemeth, G. Creston Campbell, and C.M. Foris. Journal of Pharmaceutical Sciences, Vol 19, No. 12, December 2002.
  • Degradation of a fluoropyridinyl drug in capsule formulation:  degradant identification, proposed degradation mechanism, and formulation optimization.  J. G. Chen, D.A. Markovitz, A. Y. Yang, S. Rabel, J. Pang, O. Dolinsky, L.S. Wu, M. Alasandro.  Pharmaceutical Development Technology 2000, pp. 561-570.
  • Characterization of the Solution Stability and Degradation Products of the Novel Neurotransmitter Release Enhancer 10,10,-Bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone, (DMP 543). Shelley R. Rabel, Mirwais K. Shinwari, Gregory A. Nemeth, Karl F. Blom and Michael B. Maurin.   Drug Stability, vol. 1 (No. 4), 1997, pp 224-230.
  • Determination of the pKa and pH-Solubility Behavior of an Ionizable Cyclic Carbamate, (S)-6-chloro-4-(Cyclopropylethynyl)-1,4-Dihydro-4-(Trifluoromethyl)-2H-3,1-Benzoxazin-2-one (DMP 266).  Shelley R. Rabel, Michael B. Maurin, Susan M. Rowe, and Munir A. Hussain.  Pharmaceutical Development and Technology 1 (1), 91-95 (1996).
  • Applications of Modulated Differential Scanning Calorimetry in Preformulation Studies.  Shelley R. Rabel, Janan A. Jona, and Michael B. Maurin.  Journal of Pharmaceutical and Biomedical Analysis, 21, pp. 339-345 (1999).

Student Group Advisement

  • Co-Sponsor, Student Affiliates of the American Chemical Society (SAACS)

Other Professional Experiences

  • 2010-Present, Member, Council on Undergraduate Research
  • 2009-Present, American Chemical Society
  • 1990-Present, Member, American Association of Pharmaceutical Chemists
  • Fourteen years of Research and Development experience in the Pharmaceutical Industry(DuPont Pharmaceuticals, Johnson and Johnson, Amgen)

Other

  • Personal interests:  Spending time with family, Sports (golf, skiing, football, KU basketball), Travel
  • Related Links:  rileyandrabel.com